Edison Open House: Global Healthcare 2022, page-5

"CEO of the Year The competition has been fierce. Antisense’s Mark Diamond and Rhinomed’s Michael Johnson were front runners, until last week, when Team Neuren finally – after at least 16 short biotech years – announced North America partner Acadia’s phase III Rett trial of trofinetide, formerly known as NNZ2566 or Glypromate, met its endpoints with flying colors.

The runners-up include Atomo’s John Kelly, Biotron’s Dr Michelle Miller, Genetic Signatures’ Dr John Melki, Kazia’s Dr James Garner, Pro Medicus’s Dr Sam Hupert, Proteomics’ Dr Richard Lipscombe, Rhythm Biosciences Glenn Gilbert, Telix’s Dr Behrenbruch, Universal Biosensors John Sharman and Volpara’s Dr Ralph Highnam.
"https://www.biotechdaily.com.au/media/editorials/2021_The_Year_In_Review_2.pdf